- Home
- LVLU vs SNY Comparison
LVLU vs SNY Comparison
Compare LVLU & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | SNY |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 119.4B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVLU | SNY |
|---|---|---|
| Price | $5.35 | $48.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $15.00 | ★ $61.50 |
| AVG Volume (30 Days) | 31.9K | ★ 2.6M |
| Earning Date | 11-12-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | $285,413,000.00 | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $2.53 | $6.47 |
| P/E Ratio | ★ N/A | $11.13 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $44.62 |
| 52 Week High | $18.00 | $60.12 |
Technical Indicators
Market Signals| Indicator | LVLU | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 43.35 |
| Support Level | $5.00 | $47.80 |
| Resistance Level | $6.41 | $49.24 |
| Average True Range (ATR) | 0.48 | 0.64 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 17.81 | 29.77 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.